Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orexigen obesity drug Contrave adds more Phase III success

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Results from the remaining three studies in Orexigen's registrational program for its obesity drug Contrave (bupropion/naltrexone), released July 20, more than satisfy FDA's categorical efficacy benchmark for clinically significant weight loss, and the firm said it expects to submit the NDA in the first half of 2010. Rival weight-loss drugs Qnexa (phenterimine/topiramate) from Vivus and lorcaserin (APD-356) from Arena are expected to report Phase III data in the third quarter. Contrave, a fixed combination norepinephrine reuptake inhibitor and opioid receptor antagonist, is designed to address both the behavior and reward pathways in the brain to help patients initiate and sustain weight loss. In two of the three studies, 48 percent and 56 percent of patients, respectively, lost at least 5 percent of their body weight after 56 weeks, about three times the weight lost by the placebo groups. In the third study, in patients with type 2 diabetes, 44.5 percent of patients lost more than 5 percent of their body weight, more than double the 18.9 percent on placebo. They also experienced a 0.6 percent reduction in HbA1c from baseline compared to 0.1 percent in the placebo group. FDA guidance is that either the difference between the treatment group and placebo be at least 5 percent and statistically significant or that the proportion who lose at least 5 percent of their body weight be 35 percent and also double the proportion who lose 5 percent in the placebo group, the categorical benchmark. The fourth study, reported in January, met all of its endpoints and satisfied the categorical criteria, but the relative difference in absolute weight loss fell short of the first efficacy test, a lapse the company attributed to the stringent lifestyle and behavior modification program to which both the treatment and placebo groups were subjected (1"The Pink Sheet," April 6, 2009)

You may also be interested in...

Arena, Like Rivals, Greets Mixed Phase III Obesity Results With Brave Face

Arena's release this week of surprisingly disappointing results for its obesity drug lorcaserin raises more questions about what "efficacy" means in the highly competitive space, and about the flexibility of FDA guidance for weight-management products

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered. 

OIG: FDA’s EUA Approach Allowed Bad Tests To Reach Market

A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts